Accueil - CRCL-Résistance hormonale, méthylation et cancer du sein

Sébastien Martinez, Stéphanie Sentis, Coralie Poulard, Olivier Trédan, Muriel Le Romancer. Role of PRMT1 and PRMT5 in Breast Cancer. International Journal of Molecular Sciences, 2024, 25, ⟨10.3390/ijms25168854⟩. ⟨hal-04765663⟩
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, Marie-Ange Mouret-Reynier, Olfa Derbel, et al.. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial. Nature Communications, 2024, 15 (1), pp.5931. ⟨10.1038/s41467-024-46999-x⟩. ⟨hal-04765682⟩
Sebastien Martinez, Shifei Wu, Michael Geuenich, Ahmad Malik, Ramona Weber, et al.. In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer. Nature Communications, 2024, 15, ⟨10.1038/s41467-024-49450-3⟩. ⟨hal-04947628⟩
Loïc Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, et al.. The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST. Acta Oncologica, 2024, 63, pp.411 - 417. ⟨10.2340/1651-226x.2024.32745⟩. ⟨hal-04765764⟩
Gilles Freyer, Anne Floquet, Olivier Trédan, Aurore Carrot, Carole Langlois-Jacques, et al.. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 2024, 15 (1), pp.1985. ⟨10.1038/s41467-024-45974-w⟩. ⟨hal-04549309⟩
Aina Bellver-Sanchis, Pedro A Ávila-López, Iva Tic, David Valle-García, Marta Ribalta-Vilella, et al.. Neuroprotective effects of G9a inhibition through modulation of peroxisome-proliferator activator receptor gamma-dependent pathways by miR-128. Neural Regeneration Research, 2024, 19, pp.2532 - 2542. ⟨10.4103/1673-5374.393102⟩. ⟨hal-04947683⟩

Derniers manuscrits de l'équipe

Chiffres clés